Clinical Trial Update: Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the immunogenicity of a combined DTaP-IPV-Hep B-PRP~T vaccine versus PENTAXIM and ENGERIX B in infants at 2- to 4-month schedules.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Hepatitis B
• Pertussis
• Poliomyelitis

Drugs mentioned

• DTaP-IPV-Hep B-PRP~T Combined Vaccine
• Engerix-B (hepatitis B vaccine)
• Pentaxim

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Hepatitis B, Polio | Phase 3 | Status: COMPLETED | Results posted: 2014-02-04